About Us

Home > About Us

About Us

Kv1.3 Therapeutics is a clinical stage biopharmaceutical company focused on advancing new treatment options for rare autoimmune diseases. Our initial focus is on the use of our novel Kv1.3 inhibitor, dalazatide, for the treatment of inclusion body myositis (IBM), a rare, progressively debilitating disease of the muscle.

Our portfolio is based on a novel platform of compounds which are potent and highly specific Kv1.3 inhibitors.  Our Company was founded in 2009 originally as a Washington limited liability company called Kineta One, LLC.  In October of 2017, the LLC converted to a Washington C Corporation and is now known as Kv1.3 Therapeutics, Inc.

We are led by a team of experienced scientists and industry executives dedicated to developing safer and more effective therapies for patients with rare autoimmune diseases.  Kv1.3 Therapeutics is a privately-owned virtual Seattle based company that leverages the scientific backbone of Kineta, Inc. a translational development biotech company which continues to be our largest single investor today.

Vision and Mission


To advance first in class therapeutics for rare autoimmune diseases through an efficient drug development process while aligning the interests of patients and their families, healthcare providers, as well as our investors other stakeholders.

We are focused on accelerating clinical stage drug programs to meet unmet patient needs, especially for those patients with rare and progressively debilitating diseases. Our highly virtual business model is designed not only to speed the drug development process but also to improve investor returns versus traditional industry models.


Our mission is to improve the lives of patients with rare and progressively debilitating autoimmune diseases. We feel that patients deserve better treatment options regardless of the prevalence of their disease, and that patients should not be at increased risk of infections or cancers by virtue of their drug treatment. We aim to achieve this mission by developing a new class of drugs that are more targeted with less off target effect in order to address the offending immune cells and thereby provide safer and more effective treatments.